Share on StockTwits
 

Bio-Rad Laboratories (NYSE:BIO) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a note issued to investors on Wednesday, AmericanBankingNews.com reports. The firm currently has a $131.00 target price on the stock. Zacks‘ price objective indicates a potential upside of 0.76% from the company’s current price.

Bio-Rad Laboratories (NYSE:BIO) traded down 0.23% during mid-day trading on Wednesday, hitting $129.71. 95,383 shares of the company’s stock traded hands. Bio-Rad Laboratories has a one year low of $109.76 and a one year high of $133.00. The stock’s 50-day moving average is $123.4 and its 200-day moving average is $120.2. The company has a market cap of $3.722 billion and a price-to-earnings ratio of 41.98.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.91 by $1.16. The company had revenue of $505.10 million for the quarter, compared to the consensus estimate of $529.02 million. During the same quarter last year, the company posted $1.48 earnings per share. Bio-Rad Laboratories’s revenue was up 1.3% compared to the same quarter last year. Analysts expect that Bio-Rad Laboratories will post $3.95 EPS for the current fiscal year.

Bio-Rad Laboratories, Inc (NYSE:BIO) manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.